ABN Amro Investment Solutions Reduces Position in Regeneron Pharmaceuticals, Inc. $REGN

ABN Amro Investment Solutions decreased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,784 shares of the biopharmaceutical company’s stock after selling 854 shares during the quarter. ABN Amro Investment Solutions’ holdings in Regeneron Pharmaceuticals were worth $3,814,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Salomon & Ludwin LLC bought a new stake in shares of Regeneron Pharmaceuticals in the third quarter worth approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth approximately $31,000. Traub Capital Management LLC purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth approximately $38,000. Berbice Capital Management LLC grew its position in Regeneron Pharmaceuticals by 300.0% in the 2nd quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 60 shares during the period. Finally, E Fund Management Hong Kong Co. Ltd. raised its stake in Regeneron Pharmaceuticals by 87.5% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 35 shares during the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.53, for a total transaction of $77,853.00. Following the completion of the sale, the director directly owned 17,803 shares of the company’s stock, valued at $13,860,169.59. This trade represents a 0.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Jason Pitofsky sold 2,036 shares of the business’s stock in a transaction on Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the transaction, the senior vice president directly owned 4,272 shares in the company, valued at $3,325,837.44. This trade represents a 32.28% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 3,636 shares of company stock worth $2,862,920. 7.02% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on REGN shares. Guggenheim raised their price target on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $704.00 to $708.00 and gave the company a “sector perform” rating in a report on Wednesday, October 29th. Oppenheimer restated an “outperform” rating and set a $865.00 price target (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Finally, Zacks Research cut shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $793.81.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $803.17 on Monday. The stock has a market cap of $84.91 billion, a PE ratio of 19.33, a price-to-earnings-growth ratio of 2.16 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $821.11. The firm has a fifty day moving average price of $762.17 and a 200-day moving average price of $666.58. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.13 and a quick ratio of 3.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. The company had revenue of $3.88 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the company earned $12.07 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 2.5% on a year-over-year basis. Equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Stockholders of record on Friday, February 20th will be paid a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date of this dividend is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.47%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.